medigraphic.com
ISSN 1029-3035 (Electronic)

2020, Number 2

<< Back Next >>

Mediciego 2020; 26 (2)

Use of HeberFERON® in an HIV/AIDS patient with basal cell carcinoma

Díaz-Hernández MJ, Rodríguez-Rodríguez N

Language: Spanish
References: 12
Page: 1-10
PDF size: 509.78 Kb.


ABSTRACT

Introduction: basal cell carcinoma is a malignant neoplasm of the lining epithelium. Its appearance is closely linked to exposure to sunlight. Although it constitutes 60 % of skin tumors, it is considered a malignant neoplasm with a good prognosis.
Objective: to present the case of an HIV/AIDS patient with facial basal cell carcinoma treated with HeberFERON®.
Case presentation: a 70-year-old white male patient who attended the maxillofacial surgery consultation in February 2016 to remove a three-year-old lesion on the nose. He had a history of high blood pressure, had been an HIV carrier for 16 years and had undergone surgery on five occasions for presenting basal cell carcinomas of the face. He refused surgical treatment due to complications from previous operations. For this reason, treatment with HeberFERON® was suggested, an option that he accepted. After four years, during the consultation to verify the evolution of the disease, the patient was cured and expressed his satisfaction with the procedure.
Conclusions: with the use of HeberFERON®, complete regression of the facial basal cell carcinoma that he suffered was achieved in this patient, and the performance of a non-consensual surgical act was avoided. The treatment had excellent oncological, aesthetic and psychological results, with minimal complications. The contribution of this work lies in highlighting the option of drug treatment with HeberFERON® in those cases in which patients with basal cell carcinoma do not consent to surgical intervention, with excellent results in an immunodeficient patient.


REFERENCES

  1. González AR, Londoño AM, Mejía ME, Gaitán M, Pistone M, Etchichury D. Carcinoma basocelular metastásico. Experiencia de tres casos tratados con cirugía de Mohs. Dermatol. Rev Mex [Internet]. Jul 2016 [citado 27 Jul 2017];60(4):348-53. Disponible en: https://www.medigraphic.com/pdfs/derrevmex/rmd-2016/rmd164k.pdf

  2. García-Martín E, Fernández-Tirado FJ. Tendencias en el tratamiento de los carcinomas basocelulares perioculares. Arch Soc Esp Oftalmol [Internet]. Ago 2010 [citado 25 Mar 2014];85(8):261-2. Disponible en: http://scielo.isciii.es/pdf/aseo/v85n8/editorial.pdf

  3. Kale SM, Patil SB, Khare N, Math M, Jain A, Jaiswal S. Clinicopathological analysis of eyelid malignancies - A review of 85 cases. Indian J Plast Surg [Internet]. Abr 2012 [citado 20 Mar 2014];45(1):22-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385393/

  4. Lasudry J. Prise encharge des tumeurs palpébrales: considérations générales. J Fr Ophtalmol. Dic 2011;34(10):741-54.

  5. Negrín-Cáceres Y, Cabrera-Romero AC, Cárdenas-Monzón L. Aplicación de HeberPAG en carcinoma basocelular periocular. Primeras experiencias en la Provincia de Villa Clara. Acta Med Cent [Internet]. 2015 [citado 27 Jul 2017];9(4):76-8. Disponible en: http://revactamedicacentro.sld.cu/index.php/amc/article/download/299/454

  6. Negrín-Cáceres Y, Cabrera-Romero AC, Cárdenas-Monzón L, Ferrer-Pérez A, Batista-Hernández NE. Tratamiento del carcinoma basocelular periocular con una combinación sinérgica de interferones alpha-2b y gamma. Rev Mex Oftalmol [Internet]. 2018 [citado 1 Ago2018];92(3):136-43. Disponible en: https://rmo.com.mx/portadas/rmo_92_2018_3.pdf#page=32

  7. Rodríguez-Rivas M, Méndez-Triana R, Marrero-Toledo R, Arboláez-Estrada M. Ensayos clínicos controlados, una actividad en ascenso en la provincia Villa Clara. Acta Med Cent [Internet]. 2016 [citado 27 Jul 2017];10(4):2-11. Disponible en: http://revactamedicacentro.sld.cu/index.php/amc/article/view/757/873

  8. Jiménez-Barbán Y, Vega-Pupo C, Vila-Pinillo D, Fernández-Ychaso G, Arias Núñez V, Bello Rivero I. Uso de HeberPAG en carcinoma basocelular periocular. Rev Cubana Oftalmol [Internet]. Sep 2014 [citado 20 Mar 2015];27(3):482-9. Disponible en: http://scielo.sld.cu/pdf/oft/v27n3/oft14314.pdf

  9. Armas-Morell L, Sotolongo-Díaz D. Efectividad del HeberFERON en el tratamiento del carcinoma basocelular. Universidad y Ciencia [Internet]. 2013 [citado 20 Ene 2020];27 (esp):731-41. Disponible en: http://revistas.unica.cu/index.php/uciencia/article/viewFile/1482/2157

  10. Gómez-Martínez N, Gómez Martínez N. Respuesta al tratamiento con HeberFERON desde el diagnóstico de enfermería en pacientes con neoplasia basocelular. Rev Cubana Enfermer [Internet]. Sep 2018 [citado 20 Ene 2020];34(3):e2497. Disponible en: http://scielo.sld.cu/pdf/enf/v34n3/1561-2961-enf-34-03-e2497.pdf

  11. 11 Castellano-Maturell G, Nápoles-Pastoriza DD, Niebla-Chávez R, Berenguer-Gouarnaluses M, Sánchez-Álvarez JE. HeberFERON® en el tratamiento del carcinoma basocelular. Informe de caso. 16 de Abril [Internet]. Mar 2019 [citado 20 Ene 2020];58(271):25-8. Disponible en: http://www.rev16deabril.sld.cu/index.php/16_04/article/view/776/pdf_206

  12. Drake-Sosa D, Rojas-Barlys L. Heberferon en pacientes con carcinoma basocelular tratados en el municipio Puerto Padre, Las Tunas. Rev electrón Zoilo [Internet]. 2018 [citado 20 Ene 2020];43(6):[aprox. 7 p.]. Disponible en: http://www.revzoilomarinello.sld.cu/index.php/zmv/article/view/1573/pdf_531




2020     |     www.medigraphic.com